| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
22,612 |
17,867 |
$955K |
| S8301 |
Infection control supplies, not otherwise specified |
22,157 |
17,590 |
$569K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
7,999 |
7,190 |
$337K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
12,528 |
10,441 |
$326K |
| 87428 |
|
3,395 |
3,064 |
$232K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
2,489 |
2,435 |
$207K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
2,480 |
2,434 |
$195K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
13,288 |
6,151 |
$179K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,817 |
2,563 |
$170K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,789 |
1,746 |
$151K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
10,064 |
9,300 |
$136K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
12,436 |
6,020 |
$130K |
| 99000 |
|
12,232 |
10,520 |
$124K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
1,496 |
1,473 |
$115K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
904 |
863 |
$70K |
| 99429 |
|
1,980 |
1,949 |
$64K |
| 92552 |
|
4,666 |
4,512 |
$62K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,212 |
1,078 |
$59K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
2,379 |
1,692 |
$19K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
118 |
112 |
$15K |
| 90461 |
|
2,172 |
1,823 |
$13K |
| 99050 |
|
710 |
676 |
$10K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
1,539 |
1,415 |
$10K |
| 92567 |
|
762 |
721 |
$9K |
| CP002 |
|
863 |
602 |
$8K |
| 99051 |
|
1,476 |
1,390 |
$8K |
| 86328 |
|
155 |
139 |
$6K |
| 87807 |
|
486 |
438 |
$5K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
277 |
259 |
$4K |
| 96161 |
|
1,691 |
1,655 |
$4K |
| 0071A |
|
85 |
85 |
$3K |
| 0072A |
|
83 |
83 |
$3K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
68 |
68 |
$3K |
| 81003 |
|
1,065 |
959 |
$2K |
| 86580 |
|
156 |
154 |
$1K |
| 90473 |
|
40 |
40 |
$481.25 |
| 92587 |
|
28 |
28 |
$335.36 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
20 |
16 |
$195.67 |
| 96160 |
|
66 |
65 |
$2.25 |
| 90686 |
|
2,094 |
2,044 |
$0.44 |
| 90677 |
|
237 |
235 |
$0.35 |
| 90672 |
|
406 |
402 |
$0.10 |
| 90651 |
|
102 |
101 |
$0.05 |
| 90620 |
|
94 |
92 |
$0.02 |
| 90710 |
|
172 |
166 |
$0.00 |
| 99173 |
|
4,669 |
4,508 |
$0.00 |
| 90670 |
|
981 |
963 |
$0.00 |
| 90734 |
|
125 |
120 |
$0.00 |
| 90633 |
|
256 |
248 |
$0.00 |
| 82735 |
|
13 |
13 |
$0.00 |
| 2001F |
|
1,646 |
1,603 |
$0.00 |
| 36416 |
|
1,489 |
1,376 |
$0.00 |
| 90680 |
|
464 |
454 |
$0.00 |
| 90723 |
|
573 |
559 |
$0.00 |
| 36415 |
Collection of venous blood by venipuncture |
736 |
695 |
$0.00 |
| 3008F |
|
1,644 |
1,601 |
$0.00 |
| 90647 |
|
582 |
574 |
$0.00 |
| 91307 |
|
192 |
162 |
$0.00 |
| 90660 |
|
42 |
42 |
$0.00 |
| 90656 |
|
209 |
207 |
$0.00 |
| 90696 |
|
12 |
12 |
$0.00 |
| D1208 |
Topical application of fluoride, excluding varnish |
12 |
12 |
$0.00 |